Mode
Text Size
Log in / Sign up

Galantamine showed no cognitive benefit in people with HIV-associated neurocognitive disordersWhy Galantamine Failed to Help

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that galantamine offers no cognitive benefit for HIV-associated neurocognitive disorders in people on ART.

This double-blind, randomized, placebo-controlled crossover study evaluated galantamine in people with HIV on antiretroviral therapy (PWH/ART) who had HIV-associated neurocognitive disorders. Participants received either 12 weeks of galantamine or placebo, with a 12-week follow-up period. The primary outcome was a composite neurocognitive test score, while secondary outcomes included various plasma mediators and monocyte transcriptome profiles measured by Luminex and RNAseq.

The main results indicated that composite neurocognitive test scores did not differ between the galantamine and placebo groups, with an effect size of -0.02 and a 95% confidence interval of -0.2 to 0.2 (P = 0.82). Regarding inflammatory markers, monocyte CCR2 expression was greater with galantamine than placebo (effect size 15.2%; 95% CI 5, 25.1; P = 0.006). However, no differences were observed for monocyte CD16 (P = 0.76), monocyte CD163 (P = 0.8), CD8+ T-cell CD38/HLA-DR (P = 0.54), plasma sCD163 (P = 0.36), plasma sCD14 (P = 0.46), or plasma CCL2 (P = 0.34).

Safety and tolerability data were not reported in the provided evidence. Key limitations include the lack of reported sample size, study setting, and adverse event profiles. The study suggests that galantamine does not improve neurocognitive function in this population. Clinicians should interpret these findings as indicating that galantamine is not a viable treatment option for HIV-associated neurocognitive disorders based on current evidence.

People with HIV often face brain fog that medicine hasn't fully solved.

The Surprising Truth About Brain Fog

Many people living with HIV take antiretroviral therapy to keep the virus under control. This works well for the body. But it does not always fix the brain. Some patients still struggle with memory lapses, trouble focusing, or feeling mentally slow. Doctors call this HIV-associated neurocognitive disorder.

Smoking makes these brain problems worse. It adds stress to the immune system. This creates a constant low-level fire inside the body. Scientists thought they found a way to put out that fire. They looked at a drug called galantamine.

What We Used to Hope For

Galantamine is a real medicine. It is already approved to help people with mild memory loss. It works by boosting a chemical called acetylcholine. This chemical helps the brain send messages.

Researchers also knew that nicotine, found in cigarettes, can calm down certain immune cells. They guessed that galantamine might do something similar. They hoped the drug would lower inflammation without needing cigarettes. The goal was clear: clear the brain fog and calm the immune system at the same time.

Think of your immune cells like security guards. When they are too active, they start attacking healthy tissue. This causes inflammation. This inflammation is like a traffic jam in your brain. It stops signals from getting through.

Galantamine acts like a key. It fits into a specific lock on the immune cells. This lock is called the alpha-7 nicotinic receptor. When the key turns, it should tell the guards to stand down. The theory was that this would clear the traffic jam and let the brain think faster.

The Study Snapshot

Scientists tested this idea in a real-world trial. They recruited people with HIV who were already on standard treatment. Some of them smoked, and some did not.

Everyone took the drug for 12 weeks. Half took galantamine. The other half took a fake pill that looked exactly the same. Neither the patients nor the doctors knew who got which pill. This is called a double-blind study. It removes bias from the results.

The main result was not what anyone expected. The drug did not improve brain test scores. People taking galantamine did not remember better or focus better than those taking the fake pill. The difference was zero.

The study also checked for changes in the immune system. They looked at specific markers on immune cells. One marker, called CCR2, did change. It went up by about 15 percent in the drug group.

But Here's the Catch

That 15 percent increase sounds good on paper. But it did not translate to better thinking. In fact, some other inflammatory markers went up slightly. The drug did not calm the immune system as hoped.

This doesn't mean this treatment is available yet.

The study proves that galantamine is not the magic fix for HIV brain fog. It also shows that simply blocking one receptor might not be enough. The biology of HIV-related brain issues is more complex than a simple on-off switch.

If you have HIV and worry about brain fog, do not stop your current medications. This study does not change your daily routine. It simply means galantamine is not the answer for this specific problem.

Talk to your doctor if your memory is slipping. They can check for other causes like sleep issues or vitamin deficiencies. There are still many ways to support your brain health through diet, exercise, and stress management.

Science moves slowly. This trial was only 12 weeks long. It also involved a specific type of drug. Researchers will look at other treatments that target inflammation differently.

Finding a cure for brain fog in HIV will take time. It requires understanding how the virus and the immune system interact over years. Until then, focus on what you can control today. Stay active, eat well, and keep your appointments. Your brain deserves that care.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: People with HIV on ART are highly vulnerable to non-AIDS-related comorbidities, including HIV-associated neurocognitive disorders, which are linked to persistently activated monocytes/macrophages. Smoking is a major contributor to HIV-related comorbidities. However, nicotine alone has anti-inflammatory effects, mainly through α7-nicotinic receptor (nAChR) activation. Galantamine (GAL) is an FDA-approved pro-cognitive medication that increases endogenous acetylcholine and also directly potentiates the α7-nAChR. We hypothesized that GAL would improve neurocognition in PWH, both by direct pro-cognitive effects and by reducing inflammation. We also explored whether effects differed by smoking status. DESIGN/METHODS: Smoking and nonsmoking PWH/ART participated in a double-blind, randomized, placebo-controlled crossover study of 12 weeks of GAL treatment. Primary outcomes were composite neurocognitive test score; monocyte CD16, CD163 and CCR2, and CD8 T-cell CD38/HLA-DR; and plasma sCD16, sCD163 and CCL2. Plasma hsCRP and neurofilament light chain (NFL) were also measured. Exploratory analyses included plasma mediators by Luminex and monocyte transcriptome by RNAseq. RESULTS: Neurocognition did not differ between GAL and placebo treatment (adjusted standardized difference (95% CI) -0.02 (-0.2, 0.2); P  = 0.82), with no difference by smoking status ( P  = 0.51). Monocyte CCR2 expression was 15.2% (5, 25.1) greater with GAL than placebo ( P  = 0.006). No differences were seen in monocyte CD16 ( P  = 0.76) or CD163 ( P  = 0.8), CD8 + T-cell CD38/HLA-DR ( P  = 0.54), or plasma sCD163 ( P  = 0.36), sCD14 ( P  = 0.46), or CCL2 ( P  = 0.34). NFL and hsCRP were not different, but several pro-inflammatory cytokines increased with GAL. Only modest effects were seen on monocyte gene expression. CONCLUSIONS: Galantamine for 12 weeks did not improve cognition or reduce inflammation in PWH/ART regardless of smoking status.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.